Last reviewed · How we verify
NUC-7738
At a glance
| Generic name | NUC-7738 |
|---|---|
| Also known as | Nucleotide Analogue |
| Sponsor | NuCana plc |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Safety, Pharmacokinetic and Clinical Activity Study of NUC-7738 in Patients With Advanced Solid Tumours and Lymphoma (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- NUC-7738 CI brief — competitive landscape report
- NUC-7738 updates RSS · CI watch RSS
- NuCana plc portfolio CI